Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024

1/16/24 5:30:00 PM ET

Medical/Dental Instruments

Health Care

Get the next $ARAY alert in real time by email

MADISON, Wis., Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on January 31, 2024.

The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is (877) 344-7529 (USA) or (412) 317-0088 (international), conference ID: 1227335.

A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the third quarter of fiscal 2024.

About Accuray

Accuray Incorporated (NASDAQ:ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Investor Contact

Aman Patel, CFA

Investor Relations, ICR-Westwicke

+1 (443) 450-4191

[email protected]

Media Contact

Beth Kaplan

Public Relations Director, Accuray

+1 (408) 789-4426

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-to-report-second-quarter-fiscal-2024-financial-results-on-january-31-2024-302036341.html

SOURCE Accuray Incorporated

Get the next $ARAY alert in real time by email

Date

Price Target

Rating

Analyst

2/13/2024

$9.00

Buy

ROTH MKM

6/23/2022

$7.50

Buy

B. Riley Securities

12/22/2021

$7.50

Buy

Loop Capital

Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024

Chat with this insight

Recent Analyst Ratings for $ARAY

$ARAY Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Whitters Joseph E bought $156,045 worth of shares (100,000 units at $1.56), increasing direct ownership by 22% to 561,053 units (SEC Form 4)

$ARAY SEC Filings

SEC Form 10-Q filed by Accuray Incorporated

Accuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Accuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$ARAY Financials

Live finance-specific insights

$ARAY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$ARAY Large Ownership Changes

This live feed shows all institutional transactions in real time.

Accuray Reports Fiscal 2025 First Quarter Financial Results

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024

Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results

Director Scott Byron C covered exercise/tax liability with 22,642 shares, decreasing direct ownership by 16% to 119,333 units (SEC Form 4)

Director Huss Beverly A covered exercise/tax liability with 22,642 shares, decreasing direct ownership by 11% to 187,362 units (SEC Form 4)

SVP Chief Financial Officer Pervaiz Ali covered exercise/tax liability with 3,207 shares, decreasing direct ownership by 0.81% to 390,931 units (SEC Form 4)

Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

SEC Form SC 13G filed by Accuray Incorporated

SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

$ARAY Market Insights

Live Market Insights

Long-term Customer Heidelberg University Hospital In Heidelberg, Germany, Has Selected Accuray's Radixact System, Equipped With ClearRT, Synchrony, And VOLO Ultra Optimizer Solutions, It Will Replace The Older Generation Accuray Tomotherapy System

Accuray Announced An Agreement With TrueNorth Medical Physics To Provide Radiation Oncology Departments With Third-party Support Designed To Enhance Their Department's Capabilities

Accuray's Precision Treatment System Gains Approval in China, Expanding Cancer Care Options

$ARAY Press Releases

Fastest customizable press release news feed in the world

Accuray Reports Fiscal 2025 First Quarter Financial Results

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024

Accuray Appoints Michael Murphy as VP, Corporate Controller

$ARAY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ROTH MKM initiated coverage on Accuray with a new price target

B. Riley Securities initiated coverage on Accuray with a new price target

Loop Capital initiated coverage on Accuray with a new price target

$ARAY Leadership Updates

Live Leadership Updates

Accuray Appoints Michael Murphy as VP, Corporate Controller

Robert C. Kill Joins Accuray Board of Directors

EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company's U.S. Subsidiary

Recent Analyst Ratings for
$ARAY

$ARAY
Insider Purchases

$ARAY
SEC Filings

$ARAY
Financials

$ARAY
Insider Trading

$ARAY
Large Ownership Changes

$ARAY
Market Insights

$ARAY
Press Releases

$ARAY
Analyst Ratings

$ARAY
Leadership Updates